

References and Notes

1. B. Vogelstein, N. Papadopoulos, V. E. Velculescu, S. Zhou, L. A. Diaz Jr., K. W. Kinzler, Cancer genome landscapes. *Science* **339**, 1546–1558 (2013). [Medline doi:10.1126/science.1235122](#)
2. P. van der Bruggen, V. Stroobant, N. Vigneron, B. Van den Eynde, “Tumor antigens resulting from mutations,” *Cancer Immunity* (2013), <http://cancerimmunity.org/peptide/mutations/>.
3. P. F. Robbins, Y. C. Lu, M. El-Gamil, Y. F. Li, C. Gross, J. Gartner, J. C. Lin, J. K. Teer, P. Cliften, E. Tycksen, Y. Samuels, S. A. Rosenberg, Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. *Nat. Med.* **19**, 747–752 (2013). [Medline doi:10.1038/nm.3161](#)
4. N. van Rooij, M. M. van Buuren, D. Philips, A. Velds, M. Toebes, B. Heemskerk, L. J. van Dijk, S. Behjati, H. Hilkmann, D. El Atmioui, M. Nieuwland, M. R. Stratton, R. M. Kerkhoven, C. Kesmir, J. B. Haanen, P. Kvistborg, T. N. Schumacher, Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. *J. Clin. Oncol.* **31**, e439–e442 (2013). [Medline doi:10.1200/JCO.2012.47.7521](#)
5. Y. C. Lu, X. Yao, Y. F. Li, M. El-Gamil, M. E. Dudley, J. C. Yang, J. R. Almeida, D. C. Douek, Y. Samuels, S. A. Rosenberg, P. F. Robbins, Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. *J. Immunol.* **190**, 6034–6042 (2013). [Medline doi:10.4049/jimmunol.1202830](#)
6. V. Corbière, J. Chapiro, V. Stroobant, W. Ma, C. Lurquin, B. Lethé, N. van Baren, B. J. Van den Eynde, T. Boon, P. G. Coulie, Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. *Cancer Res.* **71**, 1253–1262 (2011). [Medline doi:10.1158/0008-5472.CAN-10-2693](#)
7. J. Huang, M. El-Gamil, M. E. Dudley, Y. F. Li, S. A. Rosenberg, P. F. Robbins, T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product. *J. Immunol.* **172**, 6057–6064 (2004). [Medline](#)
8. H. Echchakir, F. Mami-Chouaib, I. Vergnon, J. F. Baurain, V. Karanikas, S. Chouaib, P. G. Coulie, A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. *Cancer Res.* **61**, 4078–4083 (2001). [Medline](#)
9. S. Mandruzzato, F. Basseur, G. Andry, T. Boon, P. van der Bruggen, A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. *J. Exp. Med.* **186**, 785–793 (1997). [Medline doi:10.1084/jem.186.5.785](#)
10. K. T. Hogan, D. P. Eisinger, S. B. Cupp 3rd, K. J. Lekstrom, D. D. Deacon, J. Shabanowitz, D. F. Hunt, V. H. Engelhard, C. L. Slingluff Jr., M. M. Ross, The

peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T lymphocytes is derived from a mutated elongation factor 2 gene. *Cancer Res.* **58**, 5144–5150 (1998). [Medline](#)

11. V. Karanikas, D. Colau, J. F. Baurain, R. Chiari, J. Thonnard, I. Gutierrez-Roelens, C. Goffinet, E. V. Van Schaftingen, P. Weynants, T. Boon, P. G. Coulie, High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. *Cancer Res.* **61**, 3718–3724 (2001). [Medline](#)
12. S. Wedén, M. Klemp, I. P. Gladhaug, M. Møller, J. A. Eriksen, G. Gaudernack, T. Buanes, Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. *Int. J. Cancer* **128**, 1120–1128 (2011). [Medline](#) [doi:10.1002/ijc.25449](#)
13. Materials and methods are available as supplementary materials on *Science* Online.
14. D. Mumberg, P. A. Monach, S. Wanderling, M. Philip, A. Y. Toledano, R. D. Schreiber, H. Schreiber, CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. *Proc. Natl. Acad. Sci. U.S.A.* **96**, 8633–8638 (1999). [Medline](#) [doi:10.1073/pnas.96.15.8633](#)
15. A. Corthay, D. K. Skovseth, K. U. Lundin, E. Røsjø, H. Omholt, P. O. Hofgaard, G. Haraldsen, B. Bogen, Primary antitumor immune response mediated by CD4+ T cells. *Immunity* **22**, 371–383 (2005). [Medline](#) [doi:10.1016/j.immuni.2005.02.003](#)
16. S. A. Quezada, T. R. Simpson, K. S. Peggs, T. Merghoub, J. Vider, X. Fan, R. Blasberg, H. Yagita, P. Muranski, P. A. Antony, N. P. Restifo, J. P. Allison, Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. *J. Exp. Med.* **207**, 637–650 (2010). [Medline](#) [doi:10.1084/jem.20091918](#)
17. Y. Xie, A. Akpınarli, C. Maris, E. L. Hipkiss, M. Lane, E. K. Kwon, P. Muranski, N. P. Restifo, P. A. Antony, Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. *J. Exp. Med.* **207**, 651–667 (2010). [Medline](#) [doi:10.1084/jem.20091921](#)
18. P. D. Greenberg, D. E. Kern, M. A. Cheever, Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells. *J. Exp. Med.* **161**, 1122–1134 (1985). [Medline](#) [doi:10.1084/jem.161.5.1122](#)
19. Z. C. Ding, L. Huang, B. R. Blazar, H. Yagita, A. L. Mellor, D. H. Munn, G. Zhou, Polyfunctional CD4⁺ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy. *Blood* **120**, 2229–2239 (2012). [Medline](#) [doi:10.1182/blood-2011-12-398321](#)
20. K. A. Shafer-Weaver, S. K. Watkins, M. J. Anderson, L. J. Draper, A. Malyguine, W. G. Alvord, N. M. Greenberg, A. A. Hurwitz, Immunity to murine prostatic tumors: Continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells. *Cancer Res.* **69**, 6256–6264 (2009). [Medline](#) [doi:10.1158/0008-5472.CAN-08-4516](#)

21. N. N. Hunder, H. Wallen, J. Cao, D. W. Hendricks, J. Z. Reilly, R. Rodmyre, A. Jungbluth, S. Gnjatic, J. A. Thompson, C. Yee, Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. *N. Engl. J. Med.* **358**, 2698–2703 (2008). [Medline doi:10.1056/NEJMoa0800251](#)
22. H. Braumüller, T. Wieder, E. Brenner, S. Aßmann, M. Hahn, M. Alkhaled, K. Schilbach, F. Essmann, M. Kneilling, C. Griessinger, F. Ranta, S. Ullrich, R. Mocikat, K. Braungart, T. Mehra, B. Fehrenbacher, J. Berdel, H. Niessner, F. Meier, M. van den Broek, H. U. Häring, R. Handgretinger, L. Quintanilla-Martinez, F. Fend, M. Pesic, J. Bauer, L. Zender, M. Schaller, K. Schulze-Osthoff, M. Röcken, T-helper-1-cell cytokines drive cancer into senescence. *Nature* **494**, 361–365 (2013). [Medline doi:10.1038/nature11824](#)
23. Z. Qin, T. Blankenstein, CD4+ T cell—mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. *Immunity* **12**, 677–686 (2000). [Medline doi:10.1016/S1074-7613\(00\)80218-6](#)
24. J. Yuan, S. Gnjatic, H. Li, S. Powel, H. F. Gallardo, E. Ritter, G. Y. Ku, A. A. Jungbluth, N. H. Segal, T. S. Rasalan, G. Manukian, Y. Xu, R. A. Roman, S. L. Terzulli, M. Heywood, E. Pogoriler, G. Ritter, L. J. Old, J. P. Allison, J. D. Wolchok, CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. *Proc. Natl. Acad. Sci. U.S.A.* **105**, 20410–20415 (2008). [Medline doi:10.1073/pnas.0810114105](#)
25. S. A. Rosenberg, J. C. Yang, R. M. Sherry, U. S. Kammula, M. S. Hughes, G. Q. Phan, D. E. Citrin, N. P. Restifo, P. F. Robbins, J. R. Wunderlich, K. E. Morton, C. M. Laurencot, S. M. Steinberg, D. E. White, M. E. Dudley, Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. *Clin. Cancer Res.* **17**, 4550–4557 (2011). [Medline doi:10.1158/1078-0432.CCR-11-0116](#)
26. S. Turcotte, A. Gros, K. Hogan, E. Tran, C. S. Hinrichs, J. R. Wunderlich, M. E. Dudley, S. A. Rosenberg, Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: Implications for adoptive cell transfer therapy. *J. Immunol.* **191**, 2217–2225 (2013). [Medline doi:10.4049/jimmunol.1300538](#)
27. S. Jones, T. L. Wang, IeM. Shih, T. L. Mao, K. Nakayama, R. Roden, R. Glas, D. Slamon, L. A. Diaz Jr., B. Vogelstein, K. W. Kinzler, V. E. Velculescu, N. Papadopoulos, Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. *Science* **330**, 228–231 (2010). [Medline doi:10.1126/science.1196333](#)
28. J. Jin, M. Sabatino, R. Somerville, J. R. Wilson, M. E. Dudley, D. F. Stronck, S. A. Rosenberg, Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment. *J. Immunother.* **35**, 283–292 (2012). [Medline doi:10.1097/CJI.0b013e31824e801f](#)